Brought to you by 
GEn1E gets option to p38 kinase inhibitor IP from UMB; option exercised
30 Jan 2020
Executive Summary
The University of Maryland, Baltimore granted GEn1E Lifesciences Inc. an exclusive option to license intellectual property surrounding selective p38 kinase inhibitors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement